广济药业(000952) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥244,847,193.28, representing a 43.63% increase compared to ¥170,474,710.18 in the same period last year[8] - Net profit attributable to shareholders reached ¥84,870,728.18, a significant increase of 247.47% from ¥24,425,204.13 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥84,666,234.46, up 262.48% from ¥23,357,648.24 year-on-year[8] - Basic earnings per share increased to ¥0.337, a rise of 247.42% compared to ¥0.097 in the same period last year[8] - Revenue for the current period reached $244.85 million, an increase of 43.63% compared to $170.47 million in the same period last year[17] - Operating profit surged to $116.84 million, reflecting a remarkable increase of 250.09% from $33.38 million year-over-year[17] - Net profit for the current period was $86.94 million, up 247.58% from $25.01 million in the previous year[17] - Earnings per share increased to $0.337, representing a growth of 247.42% compared to $0.097 in the same period last year[17] Asset and Equity - The company's total assets at the end of the reporting period were ¥1,710,998,258.43, reflecting a 4.21% increase from ¥1,641,883,229.51 at the end of the previous year[8] - The net assets attributable to shareholders increased by 11.18% to ¥844,107,503.22 from ¥759,236,775.04 at the end of the previous year[8] - The weighted average return on equity was 10.56%, an increase of 5.90 percentage points from 4.66% in the previous year[8] Cash Flow - The net cash flow from operating activities was ¥27,145,653.23, down 41.61% from ¥46,492,298.65 in the same period last year[8] - Cash generated from operating activities fell by 41.61%, down to $27.15 million from $46.49 million year-over-year[17] - Investment cash flow improved by 51.26%, with a reduction in outflows from $37.47 million to $18.26 million[17] Shareholder Information - The company had a total of 32,590 common shareholders at the end of the reporting period[12] - The largest shareholder, Hubei Changjiang Industrial Investment Group Co., Ltd., held 16.57% of the shares, totaling 41,710,801 shares[12] Operational Challenges and Future Plans - The company plans to continue expanding its market presence and invest in new product development to sustain growth[19] - The company has committed to addressing recent operational challenges, including regulatory penalties and production disruptions due to a fire incident[19] Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[27] - There were no non-operating fund occupations by controlling shareholders or their related parties during the reporting period[28] Cost Management - Operating costs decreased by 14.45%, from $88.04 million to $75.32 million, contributing to improved profitability[17] - Financial expenses increased by 6.35%, rising from $10.92 million to $11.62 million, indicating higher borrowing costs[17]